BR112013013283A2 - métodos para a radiorrotulação de uma molécula alvo biológica, e de preparação de uma composição radiofarmacêutica, precursor, uso de um aparelho sintetizador automatizado, cassete descartável, composto, e, uso de um composto - Google Patents

métodos para a radiorrotulação de uma molécula alvo biológica, e de preparação de uma composição radiofarmacêutica, precursor, uso de um aparelho sintetizador automatizado, cassete descartável, composto, e, uso de um composto

Info

Publication number
BR112013013283A2
BR112013013283A2 BR112013013283A BR112013013283A BR112013013283A2 BR 112013013283 A2 BR112013013283 A2 BR 112013013283A2 BR 112013013283 A BR112013013283 A BR 112013013283A BR 112013013283 A BR112013013283 A BR 112013013283A BR 112013013283 A2 BR112013013283 A2 BR 112013013283A2
Authority
BR
Brazil
Prior art keywords
compound
radiorotulation
precursor
preparation
methods
Prior art date
Application number
BR112013013283A
Other languages
English (en)
Portuguese (pt)
Inventor
Bard Indrevoll
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1020314.9A external-priority patent/GB201020314D0/en
Priority claimed from GBGB1106593.5A external-priority patent/GB201106593D0/en
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BR112013013283A2 publication Critical patent/BR112013013283A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013013283A 2010-12-01 2011-12-01 métodos para a radiorrotulação de uma molécula alvo biológica, e de preparação de uma composição radiofarmacêutica, precursor, uso de um aparelho sintetizador automatizado, cassete descartável, composto, e, uso de um composto BR112013013283A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1020314.9A GB201020314D0 (en) 2010-12-01 2010-12-01 Apoptosis pet imaging agents
US201161476805P 2011-04-19 2011-04-19
GBGB1106593.5A GB201106593D0 (en) 2011-04-19 2011-04-19 Radioconjugation method
PCT/EP2011/071506 WO2012072736A2 (en) 2010-12-01 2011-12-01 Radioconjugation method

Publications (1)

Publication Number Publication Date
BR112013013283A2 true BR112013013283A2 (pt) 2016-11-22

Family

ID=45063153

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013283A BR112013013283A2 (pt) 2010-12-01 2011-12-01 métodos para a radiorrotulação de uma molécula alvo biológica, e de preparação de uma composição radiofarmacêutica, precursor, uso de um aparelho sintetizador automatizado, cassete descartável, composto, e, uso de um composto

Country Status (12)

Country Link
US (2) US9493504B2 (cg-RX-API-DMAC7.html)
EP (2) EP3395373B1 (cg-RX-API-DMAC7.html)
JP (1) JP6231882B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130119957A (cg-RX-API-DMAC7.html)
CN (2) CN103269725B (cg-RX-API-DMAC7.html)
AU (1) AU2011334881A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013013283A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819347A1 (cg-RX-API-DMAC7.html)
ES (2) ES2675102T3 (cg-RX-API-DMAC7.html)
MX (1) MX2013006202A (cg-RX-API-DMAC7.html)
RU (1) RU2013122649A (cg-RX-API-DMAC7.html)
WO (1) WO2012072736A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
GB201314936D0 (en) * 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
BR112020010436A2 (pt) * 2018-01-26 2020-11-24 F. Hoffmann-La Roche Ag oligonucleotídeo radiomarcado, processos para a preparação de um oligonucleotídeo radiomarcado, uso do oligonucleotídeo radiomarcado, método para determinar a biodistribuição e farmacocinética e oligonucleotídeo

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
GB0420365D0 (en) 2004-09-14 2004-10-13 Hammersmith Imanet Ltd Radiolabelled insulin
US8241606B2 (en) 2006-12-18 2012-08-14 Ge Healthcare As Synthesis of a radiofluorinated peptide using photolabile protecting groups
US8216548B2 (en) * 2006-12-28 2012-07-10 Ge Healthcare As Radiofluorination methods
US8545809B2 (en) * 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US20080274046A1 (en) * 2007-02-20 2008-11-06 Christian Prenant Radiolabelling
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method

Also Published As

Publication number Publication date
CN104984372B (zh) 2018-11-09
CN103269725A (zh) 2013-08-28
US20170044080A1 (en) 2017-02-16
ES2929507T3 (es) 2022-11-29
JP2014500883A (ja) 2014-01-16
WO2012072736A3 (en) 2012-10-18
CN103269725B (zh) 2015-09-23
ES2675102T3 (es) 2018-07-06
AU2011334881A1 (en) 2013-06-06
EP2646060A2 (en) 2013-10-09
US20130259803A1 (en) 2013-10-03
US9493504B2 (en) 2016-11-15
EP3395373B1 (en) 2022-10-19
CN104984372A (zh) 2015-10-21
RU2013122649A (ru) 2015-01-10
MX2013006202A (es) 2013-07-29
JP6231882B2 (ja) 2017-11-15
EP2646060B1 (en) 2018-05-30
KR20130119957A (ko) 2013-11-01
EP3395373A1 (en) 2018-10-31
WO2012072736A2 (en) 2012-06-07
CA2819347A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014016287A2 (pt) composto, composição farmacêutica, método para aumentar a inclusão de exon 7 de smn2, método para aumentar a quantidade de proteína, método para o tratamento de sma
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
HUP1000069A2 (en) New salts for the preparation of pharmaceutical composition
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
EP2669289A4 (en) QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BR112013016141A2 (pt) cartucho para armazenamento de instrumentos médicos
BR112013013522A2 (pt) polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
BR112014009471A2 (pt) compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112012004173A2 (pt) "composto, composição, método para preparar uma composição, e, uso de um composto"
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]